NewsBenzingaアクチニウム・ファーマ、ESMO 2026年会議で、転移性去勢抵抗性前立腺がんにおけるHER3標的・非PSMA放射線治療薬ATNM-400の初のヒト対象第1相試験を発表へ アクチニウム・ファーマ、ESMO 2026年会議で、転移性去勢抵抗性前立腺がんにおけるHER3標的・非PSMA放射線治療薬ATNM-400の初のヒト対象第1相試験を発表へ Benzinga 2026.10.23 12:05 (GMT+0) Open on Benzinga Other news Why Microsoft Thinks Smaller, Cheaper AI Can Beat Claude and GPT Here’s How Much You Would Have Made Owning Royal Caribbean Group Stock In The Last 15 Years Nvidia says its open-source AI strategy remains intact after Jensen Huang’s exit $1000 Invested In Teck Resources 5 Years Ago Would Be Worth This Much Today 'Microsoft Executive Says Nvidia Drama Could Boost Rival Chips'- Bloomberg Nvidia says it doesn’t plan to reappoint Jensen Huang as CEO